Please login to the form below
Bioverativ
This page shows the latest Bioverativ news and features for those working in and with pharma, biotech and healthcare.
Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year
Sanofi acquired rights to sutimlimab as part of its $11.6bn takeover of Bioverativ last year under former CEO Olivier Brandicourt, and has been billed as one of the most promising
Latest news
-
Dupixent drives Sanofi again, but other new drugs are lagging
There was bad news for Genzyme’s blood disorders unit, however. Long-acting haemophilia A drug Eloctate – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – succumbed
-
EMA clears Novo Nordisk’s long-acting haemophilia A drug
Takeda’s Shire unit already has a long-acting factor VIII product on the market in Adynovate, as does Sanofi with Eloctate from its recent Bioverativ acquisition, Bayer with Kovaltry, and
-
Hudson named Brandicourt’s successor as Sanofi’s CEO
He also bolstered the company’s pipeline with acquisitions of Ablynx and Bioverativ for 3.9bn and $11.6bn, respectively, building a franchise in rare blood diseases, but missed out to
-
Bicycle Therapeutics looks to raise $86m with IPO
The company has research collaborations with AstraZeneca in respiratory, cardiovascular and metabolic disease, Bioverativ in non-malignant haematology indications, including haemophilia and with Oxurion in ophthalmology.
-
Sobi shows strong growth despite haemophilia competition
countries. Marketing rights to the drugs in the US, Canada and Japan are held by Bioverativ, which was acquired last year by Sanofi.
Dupixent drives Sanofi again, but other new drugs are lagging
EMA clears Novo Nordisk’s long-acting haemophilia A drug
Hudson named Brandicourt’s successor as Sanofi’s CEO
Bicycle Therapeutics looks to raise $86m with IPO
Sobi shows strong growth despite haemophilia competition
More from news
Approximately 3 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Biogen's spin-out, Bioverativ, had not even got past its first anniversary as a Nasdaq-listed company before being snapped up by Sanofi for $11.6bn (although this is not ... only with its rare disease focus but also enhances its portfolio of products for
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Industry appointments
Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... The firm has managed to poach Bioverativ’s senior executive Rogerio Vivaldi (pictured
-
Voyager Therapeutics appoints Matthew Ottmer as chief operating officer
the chief executive officer and president of Syntonix Pharmaceuticals - a wholly owned subsidiary of Biogen, now Bioverativ - and vice president of global operations.
Industry appointments
Voyager Therapeutics appoints Matthew Ottmer as chief operating officer
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Midweight-Senior Creative
-
Competitive Salary Offered
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- CONGREGO™ IS NOW MULTI-PLATFORM
- Onyx Health Marks Record Growth with Six New Appointments
- FDA expands use of COVID-19 antibody cocktail
- New European supply deals show Pfizer and Moderna have increased COVID-19 vaccine prices
- Ipsen’s spending spree bolsters neurology pipeline
- AMICULUM® launches Cence, a new specialist publications agency
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- Eylea set to challenge Lucentis in UK after NICE recommendation
- Onyx Health Launch Creative Studio After Record Year
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
PMHub
Mind+Matter
We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...
Latest intelligence
- Guide
- How to embrace behavioural science principles in healthcare MR...
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
